Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Seroepidemiology of Parechovirus A3 Neutralizing Antibodies, Australia, the Netherlands, and United States
  • Published Date:
    January 2019
  • Source:
    Emerg Infect Dis. 25(1):148-152
  • Language:
    English
Filetype[PDF-1.10 MB]


Details:
No Related Documents.
You May Also Like:
  1. Seroepidemiology of Saffold Cardiovirus Type 2
    Personal Author:
    Galama, Jochem; Lanke, Kjerstin; Zoll, Jan; Roivainen, Merja; van Kuppeveld, Frank;
    Published Date:
    Aug 2011
    Source:
    Emerg Infect Dis. 17(8):1572-1573.
    File Type:
    Filetype[PDF - 86.62 KB]
  2. Methicillin-Resistant Staphylococcus aureus Bloodstream Infections and Injection Drug Use, Tennessee, USA, 2015–2017
    Personal Author:
    Parikh, Meghana P.; Octaria, Rany; Kainer, Marion A.;
    Published Date:
    Mar 2020
    Source:
    Emerg Infect Dis. 26(3):446-453
    Description:
    Recently, Tennessee, USA, has seen an increase in the use of commonly injected drugs, such as heroin and fentanyl. Injection drug use (IDU) practices can lead to life-threatening methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infectio...
    File Type:
    Filetype[PDF - 991.24 KB]
  3. Role of Maternal Antibodies in Infants with Severe Diseases Related to Human Parechovirus Type 31
    Personal Author:
    Aizawa, Yuta; Watanabe, Kanako; Oishi, Tomohiro; Hirano, Harunobu; Hasegawa, Isao; Saitoh, Akihiko;
    Published Date:
    Nov 2015
    Source:
    Emerg Infect Dis. 21(11):1966-1972
    Description:
    Human parechovirus type 3 (HPeV3) is an emerging pathogen that causes sepsis and meningoencephalitis in young infants. To test the hypothesis that maternal antibodies can protect this population, we measured neutralizing antibody titers (NATs) to HPe...
    File Type:
    Filetype[PDF - 1.35 MB]
  4. Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea
    Personal Author:
    Park, Wan Beom; Perera, Ranawaka A.P.M.; Choe, Pyoeng Gyun; Lau, Eric H.Y.; Choi, Seong Jin; Chun, June Young; Oh, Hong Sang; Song, Kyoung-Ho; Bang, Ji Hwan; Kim, Eu Suk; Kim, Hong Bin; Park, Sang Won; Kim, Nam Joong; Man Poon, Leo Lit; Peiris, Malik; Oh, Myoung-don;
    Published Date:
    Dec 2015
    Source:
    Emerg Infect Dis. 21(12):2186-2189
    Description:
    We investigated the kinetics of serologic responses to Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using virus neutralization and MERS-CoV S1 IgG ELISA tests. In most patients, robust antibody responses developed by the third...
    File Type:
    Filetype[PDF - 450.83 KB]
  5. Experimental Infection and Response to Rechallenge of Alpacas with Middle East Respiratory Syndrome Coronavirus
    Personal Author:
    Crameri, Gary; Durr, Peter A.; Klein, Reuben; Foord, Adam; Yu, Meng; Riddell, Sarah; Haining, Jessica; Johnson, Dayna; Hemida, Maged G.; Barr, Jennifer; Peiris, Malik; Middleton, Deborah; Wang, Lin-Fa;
    Published Date:
    Jun 15 2016
    Source:
    Emerg Infect Dis. 22(6):1071-1074.
    Description:
    We conducted a challenge/rechallenge trial in which 3 alpacas were infected with Middle East respiratory syndrome coronavirus. The alpacas shed virus at challenge but were refractory to further shedding at rechallenge on day 21. The trial indicates t...
    File Type:
    Filetype[PDF - 736.50 KB]